C57BL/6JCya-Virmaem1flox/Cya
Common Name:
Virma-flox
Product ID:
S-CKO-12931
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Virma-flox
Strain ID
CKOCMP-66185-Virma-B6J-VA
Gene Name
Product ID
S-CKO-12931
Gene Alias
1110037F02Rik; 4930422M05Rik; Kiaa1429; mKIAA1429
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
4
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Virmaem1flox/Cya mice (Catalog S-CKO-12931) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000108307
NCBI RefSeq
NM_001081183
Target Region
Exon 2
Size of Effective Region
~1.2 kb
Detailed Document
Overview of Gene Research
VIRMA, also known as KIAA1429, is a key component of the m6A methyltransferase complex. N6 -methyladenosine (m6A) is a prevalent eukaryotic mRNA modification that regulates various biological processes like tissue development, stem cell formation, and cancer development. VIRMA is involved in guiding region-selective m6A methylation, particularly in the 3'untranslated region (3'UTR) and near stop codons of mRNAs, and is associated with alternative polyadenylation [1].
In multiple cancer types, VIRMA has shown oncogenic properties. In nasopharyngeal carcinoma, it promotes tumorigenesis and metastasis by upregulating E2F7 in an m6A-dependent manner [2]. In breast cancer, it facilitates cancer progression through m6A-dependent cytosolic HAS2 stabilization [3]. In triple-negative breast cancer, VIRMA promotes disease progression by increasing m6A-dependent KIF15 expression [4]. In non-small cell lung cancer, VIRMA-guided m6A modifications promote cancer progression via m6A-dependent degradation of DAPK3 mRNA [6]. In intrahepatic cholangiocarcinoma, VIRMA stabilizes TMED2 and PARD3B expression through an m6A-HuR-mediated mechanism, promoting cancer cell proliferation and metastasis [5].
In conclusion, VIRMA is a crucial regulator in the m6A mRNA methylation process, playing significant roles in cancer development and progression. Studies using in vitro and in vivo models, including gene-knockdown experiments, have revealed its oncogenic functions in multiple cancer types, highlighting its potential as a therapeutic target for cancer treatment.
References：
1. Yue, Yanan, Liu, Jun, Cui, Xiaolong, He, Chuan, Liu, Jianzhao. 2018. VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation. In Cell discovery, 4, 10. doi:10.1038/s41421-018-0019-0. https://pubmed.ncbi.nlm.nih.gov/29507755/
2. Zheng, Zi-Qi, Huang, Zhuo-Hui, Liang, Ye-Lin, Tang, Ling-Long, Wei, Denghui. 2023. VIRMA promotes nasopharyngeal carcinoma, tumorigenesis, and metastasis by upregulation of E2F7 in an m6A-dependent manner. In The Journal of biological chemistry, 299, 104677. doi:10.1016/j.jbc.2023.104677. https://pubmed.ncbi.nlm.nih.gov/37028765/
3. Li, Na, Zhu, Zhouting, Deng, Yufei, Kang, Yuqi, Rana, Tariq M. 2023. KIAA1429/VIRMA promotes breast cancer progression by m6 A-dependent cytosolic HAS2 stabilization. In EMBO reports, 24, e55506. doi:10.15252/embr.202255506. https://pubmed.ncbi.nlm.nih.gov/37705505/
4. Chen, Chunchun, Wang, Yanyan, Li, Yulong, Zhang, Chao. . VIRMA Facilitates Triple-Negative Breast Cancer Progression via Increasing m6A-Dependent KIF15 Expression. In Discovery medicine, 35, 787-795. doi:10.24976/Discov.Med.202335178.73. https://pubmed.ncbi.nlm.nih.gov/37811616/
5. Xu, Hongfa, Lin, Xiaowen, Li, Zhongliang, Zhan, Meixiao, He, Ke. 2023. VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization. In Journal of gastroenterology, 58, 925-944. doi:10.1007/s00535-023-02015-5. https://pubmed.ncbi.nlm.nih.gov/37391589/
6. Xu, Yongfang, Chen, Yunhao, Yao, Yinan, Cheng, Jun, Zhou, Jianying. 2021. VIRMA contributes to non-small cell lung cancer progression via N6-methyladenosine-dependent DAPK3 post-transcriptional modification. In Cancer letters, 522, 142-154. doi:10.1016/j.canlet.2021.08.027. https://pubmed.ncbi.nlm.nih.gov/34520821/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen